APA (7th ed.) Citation

Suzuki, K., Suzuki, S., Kobayashi, S., Shioda, M., Fujita, H., Haruyama, Y., . . . Hirata, K. (2026). Real-world achievement of higher standards for migraine prevention with CGRP monoclonal antibodies. Cephalalgia, 46(6), 1. https://doi.org/10.1177/03331024261453284

Chicago Style (17th ed.) Citation

Suzuki, Keisuke, Shiho Suzuki, Saro Kobayashi, Mukuto Shioda, Hiroaki Fujita, Yasuo Haruyama, Ryotaro Hida, and Koichi Hirata. "Real-world Achievement of Higher Standards for Migraine Prevention with CGRP Monoclonal Antibodies." Cephalalgia 46, no. 6 (2026): 1. https://doi.org/10.1177/03331024261453284.

MLA (9th ed.) Citation

Suzuki, Keisuke, et al. "Real-world Achievement of Higher Standards for Migraine Prevention with CGRP Monoclonal Antibodies." Cephalalgia, vol. 46, no. 6, 2026, p. 1, https://doi.org/10.1177/03331024261453284.